S

Sanofi

Global pharma company; vaccines and R&D

Quality Assurance Expert

Full-TimeUpdated on 10/15/2026Deadline 12/11/26
No salary listed
Mid, Senior
Bachelor's, Master's
Beijing, China
In Person
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • A degree in Science, Pharmacy, or equivalent is required.
  • Ideally, an MSc-level qualification in Science.
  • Three to five years of industry experience, preferably within biopharma or a related regulated industry.
  • In-depth knowledge of biologic product license application processes and associated regulatory requirements.
  • Practical experience in quality operations, quality system management, and quality risk management in a health-regulated industry.
  • Knowledge and experience in pharmaceutical manufacturing, including production processing and automation.
  • Experience in scientific and technical writing.
  • Familiarity with strategic planning, balanced judgment, and risk analysis.
  • Good English writing and speaking skills.
  • Skills in driving change, cross-functional collaboration, decision-making, people development, negotiation and influencing, business partnering, communication, leadership, and assertiveness.
  • Technical skills in quality risk management, quality systems, continuous improvement management, GxP and health-regulated requirements, and international and FDA experience.
Responsibilities
  • Ensure the project is executed in accordance with Sanofi standards and Good Practices.
  • Provide regular reporting to the IFB Quality Assurance Head.
  • Support the development, implementation, and assurance of the quality management system within IFB.
  • Support execution of the project C&Q&V strategy, C&Q&V plans, and system impact assessments.
  • Assist in preparing and executing DQ, SAT, FAT, IQ, OQ, and nP-PQ protocols, final CQ reports, and the VMP.
  • Interact with relevant interfaces to share benchmarks and best practices.
  • Ensure consistency of turnover packages for system owners.
  • Support regular tracking of actual project costs and progress in quality assurance.
  • Support compliance with Sanofi guidelines and standards for cost and scheduling.
  • Promote quality culture, quality awareness, GMP compliance, and continuous improvement across project functions and organizational levels and at future sites to fulfill GMP requirements.
  • Conduct quality oversight activities in line with IFB planning and project requirements, including drafting, reviewing, and approving documentation.
  • Act as the project’s responsible Quality Subject Matter Expert in quality assurance and ensure quality compliance throughout project execution.
  • Participate in project team meetings, planning and scheduling sessions, and related project activities to plan and execute key quality risk management deliverables effectively.
  • Support reporting of key project-related quality deliverables and communicate and escalate quality risks to appropriate management levels in a timely and effective manner.
  • Develop, update, and promote Sanofi global quality documentation and global procedures.
  • Contribute to the digital strategy and transformation through effective communication with the project.
Desired Qualifications
  • Industry experience preferably within biopharma or a related regulated industry.
  • An MSc-level qualification in Science.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...

U.S. Securities and Exchange Commission
Sep 20th, 2026
8-K

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)